Aurisco Pharmaceutical - Public Comps and Valuation Multiples

Aurisco Pharmaceutical Overview

About Aurisco Pharmaceutical

Aurisco Pharmaceutical Co Ltd is engaged in production and sales of specialty APIs and pharmaceutical intermediates. The company's products include API's and Intermediates. Its products are supplied to Asia, Europe, America and Middle East through a well-established sales network.

Founded

1998

HQ

Employees

n/a

Website

aurisco.com

Sectors

Drug Development & Therapeutics
Small Molecules
BioTech
DeepTech

Financials

LTM Revenue $241M

LTM EBITDA $81.8M

EV

$1.3B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Aurisco Pharmaceutical Financials

As of September 2025, Aurisco Pharmaceutical reported last 12-month revenue of $241M and EBITDA of $81.8M.

In the same period, Aurisco Pharmaceutical generated $143M in LTM gross profit and $62.8M in net income.

See Aurisco Pharmaceutical valuation multiples based on analyst estimates

Aurisco Pharmaceutical P&L

In the most recent fiscal year, Aurisco Pharmaceutical reported revenue of $207M and EBITDA of $71.7M.

Aurisco Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Aurisco Pharmaceutical valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$241M	XXX	$207M	XXX	XXX	XXX
Gross Profit	$143M	XXX	$121M	XXX	XXX	XXX
Gross Margin	59%	XXX	59%	XXX	XXX	XXX
EBITDA	$81.8M	XXX	$71.7M	XXX	XXX	XXX
EBITDA Margin	34%	XXX	35%	XXX	XXX	XXX
EBIT	$72.6M	XXX	$57.8M	XXX	XXX	XXX
EBIT Margin	30%	XXX	28%	XXX	XXX	XXX
Net Profit	$62.8M	XXX	$49.8M	XXX	XXX	XXX
Net Margin	26%	XXX	24%	XXX	XXX	XXX
Net Debt	XXX	XXX	$22.1M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Aurisco Pharmaceutical including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $241M. EBITDA for the last twelve months was $81.8M. In the most recent fiscal year, Aurisco Pharmaceutical achieved $207M in revenue and $71.7M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$241M	Analyst estimates available to subscribers	$207M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$143M	Analyst estimates available to subscribers	$121M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	59.3% gross margin	Analyst estimates available to subscribers	58.6% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$81.8M	Analyst estimates available to subscribers	$71.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	34.0% EBITDA margin	Analyst estimates available to subscribers	34.7% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$72.6M	Analyst estimates available to subscribers	$57.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	30.1% EBIT margin	Analyst estimates available to subscribers	27.9% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$62.8M	Analyst estimates available to subscribers	$49.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	26.1% net profit margin	Analyst estimates available to subscribers	24.0% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$22.1M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Aurisco Pharmaceutical

This financial data table provides comprehensive performance metrics for Aurisco Pharmaceutical, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Aurisco Pharmaceutical generated $241M in revenue over the last twelve months.
The company achieved $81.8M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $143M.
Net income over the last twelve months reached $62.8M.

Fiscal Year Performance

In the most recent fiscal year, Aurisco Pharmaceutical reported $207M in total revenue.
Fiscal year EBITDA was $71.7M.
The company maintained a gross profit margin of 58.6% in the most recent fiscal year.
EBITDA margin for the fiscal year was 34.7%.
Net profit margin reached 24.0% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Aurisco Pharmaceutical. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Aurisco Pharmaceutical Stock Performance

Aurisco Pharmaceutical has current market cap of CNY 9.1B (or $1.3B), and EV of CNY 9.0B (or $1.3B).

Market Cap Evolution

Aurisco Pharmaceutical Stock Data

As of October 17, 2025, Aurisco Pharmaceutical's stock price is CNY 22 (or $3).

See Aurisco Pharmaceutical trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.3B	$1.3B	XXX	XXX	XXX	XXX	$0.15

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Aurisco Pharmaceutical Valuation Multiples

Aurisco Pharmaceutical's trades at 6.1x EV/Revenue multiple, and 17.6x EV/EBITDA.

See valuation multiples for Aurisco Pharmaceutical and 15K+ public comps

Aurisco Pharmaceutical Financial Valuation Multiples

As of October 17, 2025, Aurisco Pharmaceutical has market cap of $1.3B and EV of $1.3B.

Equity research analysts estimate Aurisco Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Aurisco Pharmaceutical has a P/E ratio of 20.2x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$1.3B	XXX	$1.3B	XXX	XXX	XXX
EV (current)	$1.3B	XXX	$1.3B	XXX	XXX	XXX
EV/Revenue	5.2x	XXX	6.1x	XXX	XXX	XXX
EV/EBITDA	15.5x	XXX	17.6x	XXX	XXX	XXX
EV/EBIT	17.4x	XXX	21.9x	XXX	XXX	XXX
EV/Gross Profit	8.9x	XXX	n/a	XXX	XXX	XXX
P/E	20.2x	XXX	25.5x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-43.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Aurisco Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Aurisco Pharmaceutical Margins & Growth Rates

Aurisco Pharmaceutical's last 12 month revenue growth is 20%

Aurisco Pharmaceutical's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Aurisco Pharmaceutical's rule of 40 is 52% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Aurisco Pharmaceutical's rule of X is 83% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Aurisco Pharmaceutical and other 15K+ public comps

Aurisco Pharmaceutical Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	20%	XXX	20%	XXX	XXX	XXX
EBITDA Margin	34%	XXX	35%	XXX	XXX	XXX
EBITDA Growth	31%	XXX	22%	XXX	XXX	XXX
Rule of 40	52%	XXX	54%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	83%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	7%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	10%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	31%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial